Drug Candidates and Drug Delivery Systems for Tuberculosis Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 13106
Special Issue Editor
Interests: drug delivery; medicinal chemistry; drug discovery and development; antimycobacterial agents; antiviral agents; tuberculosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tuberculosis (TB) is the leading cause of death from a bacterial infection worldwide, causing an estimated 1.5 million of deaths in 2020. The spread of drug-resistant infections strongly limits treatment options and underscores the importance of finding new drugs, new bacterial targets, as well as innovative delivery systems to improve available therapeutic tools. An urgent response is then required to prevent and treat infections, limit the spread of resistance, and foster progress towards the WHO End TB strategy goal of a 90% reduction in deaths and an 80% reduction in the TB incidence rate by 2030, compared to the 2015 baseline.
This Special Issue aims to summarize recent research in the field of TB drug development, discussing state-of-the art advances and latest development in the field and covering all the aspects and stages of investigation of innovative candidates for TB treatment, including innovative delivery protocols of both existing and novel antimycobacterial agents.
Potential topics to be covered include, but are not limited to:
- Development of novel and effective antimycobacterial agents;
- Innovative drug delivery systems for TB treatment;
- Innovative strategies to overcome drug resistance;
- Emerging molecular targets for TB drug discovery;
- Host-targeted therapies.
Dr. Sara Consalvi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- medicinal chemistry
- tuberculosis
- TB drug discovery and development
- drug resistance
- antimycobacterials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.